CD19/BCMA chimeric antigen receptor T cells / Zhejiang University  >>  Phase 1
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CD19/BCMA chimeric antigen receptor T cells / Zhejiang University
ChiCTR2100049920: A clinical study on the safety and effectiveness of CD19/BCMA chimeric antigen receptor T cells in the treatment of auto-antibody-mediated autoimmune diseases and HLA antibody-positive status before allogeneic hematopoietic stem cell transplantation

Recruiting
1
60
 
CAR-T cell therapy
the First Affiliated Hospital, Zhejiang University School of Medicine; the First Affiliated Hospital, Zhejiang University School of Medicine, National Natural Science Foundation of China
autoimmune diseases
 
 
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

Recruiting
1
9
RoW
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University, Yake Biotechnology Ltd.
Systemic Lupus Erythematosus, Autoimmune Diseases
03/22
09/22
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus

Recruiting
1
15
RoW
GC012F injection, CD19-BCMA CAR-T cells
Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd.
CAR-T
10/23
04/25
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Recruiting
1
75
RoW
CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection
Zhejiang University, Yake Biotechnology Ltd.
POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis
10/24
10/24
NCT05085444: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

Recruiting
1
9
RoW
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University, Yake Biotechnology Ltd.
Scleroderma, Autoimmune Diseases
10/24
10/24
NCT05085431: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome

Recruiting
1
9
RoW
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University, Yake Biotechnology Ltd.
Sjogren's Syndrome, Autoimmune Diseases
11/24
11/24
NCT05085418: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis

Recruiting
1
9
RoW
Assigned Interventions CD19/BCMA CAR T-cells
Zhejiang University, Yake Biotechnology Ltd.
Immune Nephritis, Autoimmune Diseases, Lupus Nephritis
11/24
11/24

Download Options